Načítá se...
The Icelandic founder mutation BRCA2 999del5: analysis of expression
INTRODUCTION: A founder mutation in the BRCA2 gene (BRCA2 999del5) accounts for 7–8% of female breast cancers and for 40% of male breast cancers in Iceland. If expressed, the mutant gene would encode a protein consisting of the first 256 amino acids of the BRCA2 protein. The purpose of this study wa...
Uloženo v:
| Vydáno v: | Breast Cancer Res |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2004
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC468616/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15217494/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/bcr785 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|